# ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

> **NCT07448610** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (estimated)

## Conditions studied

- Spinal Muscular Atrophy

## Interventions

- **DRUG:** Onasemnogene Abeparvovec-brve

## Key facts

- **NCT ID:** NCT07448610
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2032-05-03
- **Final completion:** 2032-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07448610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07448610, "ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07448610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*